Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimacimab + Wegovy
- Development stage
- Phase 2
- Lead developer
- Skye Bioscience
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
- Administration
- Subcutaneous
01
Overview
Nimacimab + Wegovy is an investigational combination of nimacimab, a peripherally restricted negative allosteric modulating monoclonal antibody targeting cannabinoid receptor 1 (CB1), and Wegovy (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist. Developed by Skye Bioscience, the combination is being evaluated for the treatment of obesity and overweight. Nimacimab is designed to avoid central nervous system penetration, thereby minimizing the neuropsychiatric side effects historically associated with small-molecule CB1 antagonists. Wegovy contributes to appetite reduction and glycemic control. The combination is being evaluated in the Phase 2a CBeyond clinical trial (NCT06577090), where it has demonstrated clinically meaningful weight loss and improved body composition compared to semaglutide alone.
- Other names
- nimacimab + semaglutide
02
Targets
CNR1 (Cannabinoid receptor 1)GLP1R (GLP-1R)
Beyond the preview
Go deeper on nimacimab + Wegovy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimacimab + Wegovy.